Home › Biomarkers › PIK3CA
PIK3CA testing: what it means for you
Waiting on test results can feel like one more hard thing, for you and the people who love you. Here's what the PIK3CA test looks for and how it can help your care team pick the treatment most likely to work for you.
ℹ️ General information to help you and your loved ones talk with your care team, not medical advice. Read our disclaimer.
Matters most in: Breast cancer
The quick guide
What the test looks for: Mutations in the PIK3CA gene, part of a cell growth pathway (PI3K/AKT). Found in about 4 in 10 hormone receptor-positive, HER2-negative breast cancers.
Why it matters
In advanced HR-positive, HER2-negative breast cancer, a PIK3CA (or related AKT1/PTEN) change can open the door to drugs that block this pathway, usually after or alongside hormone therapy.
Treatments it can point to
- PI3K/AKT pathway drugs such as alpelisib, inavolisib or capivasertib, given with hormone therapy
Only your care team can say which treatment fits you. Drug approvals depend on cancer type, stage and prior treatment.
Tissue vs. blood testing
Tissue or a blood (liquid biopsy) test. If a blood test is negative, a tissue test may still find it.
Most tests use a piece of tumor tissue from a biopsy or surgery. Some can also use a blood sample (a 'liquid biopsy') that looks for tumor DNA floating in the blood. Blood tests are easier and faster, but they can miss a change that a tissue test would find, so a negative blood test is often followed by a tissue test.
❓ Questions you and your loved ones can ask
- Has my tumor been tested for PIK3CA, AKT1 and PTEN?
- What side effects, like high blood sugar, should I watch for?
- When will my results be back, and will treatment wait for them?
- Will my insurance cover this test?
Written by the Cancer Side Effects Guide team from FDA labels and leading cancer centers. Not medical advice. · Last updated: October 15, 2026 · How we write
Sources
- FDA: List of companion diagnostics (PIK3CA tests)
- Memorial Sloan Kettering: Breast Cancer Chemotherapy, Hormone & Targeted Therapy
- Memorial Sloan Kettering: Targeted Therapy & Precision Oncology
- NCI: Biomarker Testing for Cancer Treatment
- FDA: List of Cleared or Approved Companion Diagnostic Devices
- NCCN Guidelines for Patients: Invasive Breast Cancer, 2026
- NCCN Guidelines for Patients: Ductal Carcinoma in Situ (Stage 0 Breast Cancer), 2026
- NCCN Guidelines for Patients: Metastatic Breast Cancer, 2026
- NCCN Guidelines for Patients: Inflammatory Breast Cancer, 2026